Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.

Read More
Drugs Health Pharma

Roche arm to buy breast cancer portfolio from Regor for $850 million

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.

Read More
Drugs Health Pharma

Henlius, Organon trial drug meets goal of an absence of breast cancer

Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.

Read More
Drugs Health Pharma

AstraZeneca-Daiichi Sankyo’s breast cancer drug fails in late-stage trial

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.

Read More
Drugs Health Pharma

GenX faces a higher risk of 17 cancer types than older generation

Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in.

Read More
Drugs Health Pharma

UK watchdog blocks AstraZeneca, Daiichi’s breast cancer drug

Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.

Read More
Drugs Health Pharma

AstraZeneca’s trial breast cancer drug fails to meet primary goals

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

Read More
Drugs Health Pharma

AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival

HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.

Read More
Drugs Health Pharma

Novartis AG to buy Mariana Oncology for $1 billion to build RLT assets

HQ Team May 2, 2024: Novartis AG will buy a US-based biotechnology company Mariana Oncology to expand its cancer portfolio for $1 billion..

Read More
Drugs Health Pharma

A new oral drug may stop triple-negative breast cancer in its tracks

HQ Team February 8, 2024: Australian scientists may have found a drug to treat triple-negative breast cancer without any toxic effects, according to.

Read More
X